Skip to content

Latest

Cardinal tool kit warns seniors of Rx misuse

The Cardinal Health Foundation and the Ohio State University College of Pharmacy are releasing a new, interactive tool kit designed to educate senior citizens about how to avoid misuse of prescription drugs.

No injunctive relief in Express Scripts-Walgreens suit

No injunctive relief in Express Scripts-Walgreens suit

An arbitrator has denied injunctive relief to Walgreen Co. and Express Scripts Inc. in the pharmacy benefit manager’s lawsuit against the drug chain. Walgreens issued a statement Wednesday announcing the arbitrator’s ruling, which it said was made Sunday evening.

New coalition emerges to oppose PBM merger

A new coalition of consumers, businesses and community pharmacists nationwide has formed to speak out against the proposed merger of pharmacy benefit managers Express Scripts Inc. and Medco Health Solutions Inc.

Prasco to distribute Aspen branded drugs

Prasco Laboratories has been named the exclusive U.S. distributor and pharmaceutical services provider for Aspen Global branded prescription drugs. Prasco said Tuesday that Aspen Global, a subsidiary of South Africa-based Aspen Pharmacare Holdings Ltd., is Africa’s largest pharmaceutical company.

Sandoz to add Falcon eye products from Alcon

The ophthalmic and otic products of Falcon Pharmaceuticals Ltd., the U.S. generics business of Alcon Inc., are being brought under the Sandoz umbrella. Sandoz, the generic pharmaceuticals arm of Novartis, said Tuesday that the Falcon products are slated to become part of its U.S.

Lannett ships three new generics

Lannett Co. has launched a trio of new generic drug products recently approved by the Food and Drug Administration. The new generic medications include two appetite suppressants — diethylpropion tablets (25 mg) and phentermine HCI capsules (37.

Teva wraps up Cephalon acquisition

Teva Pharmaceutical Industries Ltd. has closed its acquisition of Cephalon Inc. Teva said that as of Friday, Cephalon became a wholly owned subsidiary of and ceased to be traded on Nasdaq. The two pharmaceutical companies unveiled the $6.8 billion deal this past spring.